outperform price
earn report chang price
thesi updat bit slow note time
around apologiesbut blame travel schedul
said give us advantag put today
context overal thought report solid organ
rev beat consist perform key segment
breast health diagnost mdx continu gift
keep give consum dd thing
noteworthi us recent acquisit
faxitron focal perform realli well mid teen
nice contributor given deal annual
gyn turn growth solid contribut give
confid segment sustain msd
impli ep guidanc year also translat decent
margin expans yoy
understand guid given execut
histori believ set rais stori
context see today weak buy opportun
rais ep estimate slightli pt came tad
group multipl contract pt price-to-earnings
like
major busi segment
cyno flat sign bottom growth expect
gm improv manufactur cost better
like
guid well st
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
like
major busi segment
cyno flat sign bottom growth expect
gm improv manufactur cost improv mix
like
guid well st
blood revenu declin significantli
ssi mm month consolid
slightli dilut ep full year
molecular lead dx dx said low msd
skelet medic aesthet lower
guid includ medic devic tax inclus
expens greater prior year mm
absenc fx hedg gain
gm lower mfg cost better mix
breast health tough comp season weaker
system ship us
system convert
molecular remain main driver
capit place us panther front execut low bar capital-expenditure
us q/q growth past quarter
incent improv
myosur get line extens support product
market stabl custom back
new product omni launch omni lock seal
becom divers
easi comp
ex-revenu revers prior period cyno would flat
bodi contour women health continu struggl
skin product well
gm mix tariff ship cost increas
tax came
tuck-in acquisit boost rev
capit place us panther front execut low bar capital-expenditure
work close w/ lab drive panther volum w/ test custom use
footprint west eu grown direct mani countri breast health dx increasingli direct surgic get
asia pac similar w/ japan underdevelop one
breast health convert asian analog
cyno build throughout year
didnt benefit pull-forward breast
valuat methodolog base mix discount cash flow analysi rel valuat multipl
failur execut cyno weigh sentiment multipl higher expect declin mammographi
margin expans thesi doesnt play due higher invest turn around busi
articl articl
time dissemin novemb
analyst jon bristow vijay kumar primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
